États-Unis · Plateformes & données · MarketBeat

Vertex Highlights Kidney Pipeline as Povetacicept Cuts Proteinuria 52% in Phase III

Publié par MarketBeat · États-Unis il y a 1 h

Vertex Pharmaceuticals (NASDAQ:VRTX) outlined updates across its kidney disease pipeline at the American Society of Nephrology Kidney Week 2026, highlighting data for povetacicept…

Lire l'article complet sur MarketBeat Connectez-vous pour sauvegarder

MarketNews présente le titre et le résumé publiés par le média. L'article complet se lit sur le site de l'éditeur. (www.marketbeat.com)

Vertex Highlights Kidney Pipeline as Povetacicept Cuts Proteinuria 52% in Phase III

À lire aussi

Global X Equal Weight Can Insurance Idx ETF declares CAD 0.06 dividend

Memory Stocks Are Plummetting. Jensen Huang Says the Bears Have It Wrong.

US accuses government contractor of leaking classified info to girlfriend’s Substack

Hooters closes 35-year-old location after shutting 55 restaurants

SpaceX’s 80,000 Cell Site Push A Win For AST SpaceMobile, Ericsson, Nokia, NextNav, Among Others, Says Roth Capital

Tryg (CPSE:TRYG) Stock Looks Below Fair Value On Capital Returns

Vertex Highlights Kidney Pipeline as Povetacicept Cuts Proteinuria 52% in Phase III

Partager

À lire aussi

Global X Equal Weight Can Insurance Idx ETF declares CAD 0.06 dividend

Memory Stocks Are Plummetting. Jensen Huang Says the Bears Have It Wrong.

US accuses government contractor of leaking classified info to girlfriend’s Substack

Hooters closes 35-year-old location after shutting 55 restaurants

SpaceX’s 80,000 Cell Site Push A Win For AST SpaceMobile, Ericsson, Nokia, NextNav, Among Others, Says Roth Capital

Tryg (CPSE:TRYG) Stock Looks Below Fair Value On Capital Returns